Clinical trials recruiting in Cape Town, South Africa

Phase breakdown

Conditions recruiting in Cape Town, South Africa

Recruiting trials in Cape Town, South Africa

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
  NCT07044297 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
  NCT07662109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
  NCT06664619 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
  NCT07071623 · Phase: Phase 3 · Ages: 16 Years to 30 Years · Sex: Female
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
  NCT07613307 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
  NCT06132893 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
  NCT07598396 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
  NCT07563309 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
  NCT05562466 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
  NCT05039619 · Phase: Phase 2 · Ages: 5 Years to 17 Years · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
  NCT07276581 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
  NCT07276724 · Phase: Phase 3 · Ages: 12 Years to 80 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
  NCT06023589 · Phase: Phase 3 · Ages: 5 Years to 11 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
  NCT06337032 · Phase: Phase 4 · Ages: 1 Month and older · Sex: All (male and female)
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.
  NCT06617091 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female)
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female)
• B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV
  NCT05923333 · Phase: Not applicable (e.g. observational or device study) · Ages: 0 Days to 50 Years · Sex: All (male and female)
• B.R.A.I.N in People Living With HIV Study
  NCT06466642 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 50 Years · Sex: All (male and female)
• Brief Transdiagnostic Treatment for Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) in South Africa
  NCT06289621 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
  NCT04375800 · Phase: Phase 2 · Ages: 4 Weeks to 11 Years · Sex: All (male and female)
• Doravirine Dose Optimisation in Pregnancy
  NCT05630638 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
  NCT06932263 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female)
• Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  NCT05714085 · Phase: Phase 2, Phase 3 · Ages: 29 Days to 17 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Evaluating the Safety and Immunogenicity of MTBVAC
  NCT05947890 · Phase: Phase 2 · Ages: 12 Years to 55 Years · Sex: All (male and female)
• Evaluation of Long-Acting Injectable (LAI) and Teen Clubs in Adolescents (ATTUNE).
  NCT06721078 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 19 Years · Sex: All (male and female)
• High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
  NCT04521803 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• HoFH, the International Clinical Collaborators Registry
  NCT04815005 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Implementing Depression and Adherence Treatment
  NCT07032363 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging
  NCT05602376 · Phase: Not applicable (e.g. observational or device study) · Ages: 15 Years and older · Sex: Male
• Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
  NCT04145258 · Phase: Phase 3 · Ages: 15 Years and older · Sex: All (male and female)
• International Registry for Men With Advanced Prostate Cancer (IRONMAN)
  NCT03151629 · Phase: Not specified · Ages: 21 Years and older · Sex: Male
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
  NCT05682378 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female)
• Mentor Moms+ Study
  NCT06962592 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years and older · Sex: Female
• National Blood Pressure Screening in Children to Improve Paediatric Healthcare in South Africa
  NCT05982847 · Phase: Not specified · Ages: 5 Years to 18 Years · Sex: All (male and female)
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
  NCT05222529 · Phase: Phase 2 · Ages: 6 Years to 11 Years · Sex: All (male and female)
• Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
  NCT06451770 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
  NCT06133972 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female)
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
  NCT06485154 · Phase: Phase 4 · Ages: 15 Years and older · Sex: All (male and female)
• PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.
  NCT06807736 · Phase: Not specified · Ages: 15 Years and older · Sex: All (male and female)
• Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
  NCT05553236 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female)
• Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis
  NCT04700579 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female)
• Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
  NCT05580666 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa
  NCT05624931 · Phase: Not applicable (e.g. observational or device study) · Ages: 15 Years and older · Sex: Female
• Remote Ischaemic Conditioning in STEMI Patients in AFRICA
  NCT04813159 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
  NCT05835479 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
  NCT05712200 · Phase: Phase 3 · Ages: 65 Years and older · Sex: All (male and female)
• The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care
  NCT06554223 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
  NCT07301736 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Universal Test and Connect for HIV Service Delivery in South Africa
  NCT06408142 · Phase: Not specified · Ages: 12 Years and older · Sex: All (male and female)
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Cape Town, South Africa?

77 recruiting trials have at least one study site in Cape Town, South Africa.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.